UZH-Logo

Parameters for successful monthly extended dosing of darbepoetin-a in patients under going hemodialysis


Trachsler, J; Glück, Z; Dickenmann, M; Gauthier, T; Brünisholz, M; Martin, P Y; Brunier, M; Wahl, C; Wüthrich, R P (2009). Parameters for successful monthly extended dosing of darbepoetin-a in patients under going hemodialysis. Clinical Nephrology, 71:697-702.

Abstract

Aim: To document the feasibility and report the results of dosing darbepoetin-a at extended intervals up to once
monthly (QM) in a large dialysis patient population. Material: 175 adult pa tients treated, at 23 Swiss hemodialysis centres, with stable doses of any erythropoiesis-stimulating agent who were switched by their physicians to darbepoetin-a treatment at prolonged dosing
intervals (every 2 weeks [Q2W] or QM).
Method: Multicentre, prospective, observational study.
Patients’ hemoglobin (Hb) levels and other data were recorded 1 month before conversion (base line) to an extended darbepoetin-a dosing interval, at the time of conversion, and once monthly there after up to the
evaluation point (maximum of 12 months or until loss to follow-up).
Results: Data for 161 evaluable patients from 23 sites were included in the final analysis. At 1 month prior
to conversion, 73% of these patients were receiving darbepoetin-a weekly (QW) and 27% of the patients biweekly (Q2W). After a mean follow-up of 9.5 months, 34% received
a monthly (QM) dosing regimen, 52% of the patients were receiving darbepoetin-a Q2W, and 14% QW. The mean (SD) Hb concentration at base line was 12.3 ± 1.2 g/dl, compared
to 11.9 ± 1.2 g/dl at the evaluation point. The
corresponding mean weekly darbepoetin-a dose was 44.3 ± 33.4 μg at baseline and 37.7 ± 30.8 μg at the evaluation point.
Conclusions: Conversion to extended darbepoetin-a dosing intervals of up to QM, with maintenance of initial Hb concentrations, was successful for the majority of stable dialysis patients.

Aim: To document the feasibility and report the results of dosing darbepoetin-a at extended intervals up to once
monthly (QM) in a large dialysis patient population. Material: 175 adult pa tients treated, at 23 Swiss hemodialysis centres, with stable doses of any erythropoiesis-stimulating agent who were switched by their physicians to darbepoetin-a treatment at prolonged dosing
intervals (every 2 weeks [Q2W] or QM).
Method: Multicentre, prospective, observational study.
Patients’ hemoglobin (Hb) levels and other data were recorded 1 month before conversion (base line) to an extended darbepoetin-a dosing interval, at the time of conversion, and once monthly there after up to the
evaluation point (maximum of 12 months or until loss to follow-up).
Results: Data for 161 evaluable patients from 23 sites were included in the final analysis. At 1 month prior
to conversion, 73% of these patients were receiving darbepoetin-a weekly (QW) and 27% of the patients biweekly (Q2W). After a mean follow-up of 9.5 months, 34% received
a monthly (QM) dosing regimen, 52% of the patients were receiving darbepoetin-a Q2W, and 14% QW. The mean (SD) Hb concentration at base line was 12.3 ± 1.2 g/dl, compared
to 11.9 ± 1.2 g/dl at the evaluation point. The
corresponding mean weekly darbepoetin-a dose was 44.3 ± 33.4 μg at baseline and 37.7 ± 30.8 μg at the evaluation point.
Conclusions: Conversion to extended darbepoetin-a dosing intervals of up to QM, with maintenance of initial Hb concentrations, was successful for the majority of stable dialysis patients.

Citations

4 citations in Web of Science®
4 citations in Scopus®
Google Scholar™

Downloads

1 download since deposited on 22 Jun 2009
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Nephrology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2009
Deposited On:22 Jun 2009 15:13
Last Modified:05 Apr 2016 13:16
Publisher:Dustri-Verlag Dr Karl Feistle
ISSN:0301-0430
PubMed ID:19473639
Permanent URL: http://doi.org/10.5167/uzh-19391

Download

[img]Filetype: PDF - Registered users only
Size: 449kB

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations